NCT01108458终止2 期
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
George Albert Fisher1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2010年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Overall Response Rate by RECIST Criteria
研究概览
简要总结
A phase 2 study combining pertuzumab with erlotinib for patients with gemcitabine refractory pancreatic adenocarcinoma
详细描述
A single-institution, single-arm phase 2 study investigating pertuzumab and erlotinib as a palliative regimen in the treatment of locally-advanced or metastatic pancreatic adenocarcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •3.1 Inclusion Criteria
- •3.1.1 Histologically-confirmed pancreatic adenocarcinoma
- •3.1.2 One or more locally-advanced or metastatic lesions measurable in at least one dimension by modified RECIST criteria (v1.1)^13 within 4 weeks prior to entry of study
- •3.1.3 Prior therapy (1 or more):
- •3.1.3.1 Disease progression following therapy with gemcitabine
- •3.1.3.2 Intolerance to gemcitabine
- •3.1.3.3 Disease recurrence within 12 months following adjuvant gemcitabine
- •3.1.4 Age >= 18
- •3.1.5 ECOG performance status 0-2
- •3.1.6 Laboratory values <= 2 weeks prior to enrollment:
- •Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500/mm^3)
- •Platelets (Plt) >= 100,000/mm^3
- •Hemoglobin (Hgb) >= 9 g/dL
- •Serum creatinine <= 1.5 x ULN
- •Serum bilirubin <= 1.5 x ULN (<= 3.0 x ULN if liver metastases present)
- •Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) <= 3.0 x ULN. (<= 5.0 x ULN if liver metastases present). ERCP or percutaneous stenting may be used to normalize the liver function tests
- •3.1.7 Echocardiogram or MUGA scan demonstrating LVEF >= 50% within 4 weeks of trial entry
- •3.1.8 Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •3.2 Disease-Specific Exclusion Criteria
- •3.2.1 Prior therapy with EGFR-targeted agents
- •3.2.2 If history of other primary cancer, subject will be eligible only if she or he has:
- •Curatively resected non-melanomatous skin cancer
- •Curatively treated cervical carcinoma in situ
- •Other primary solid tumor curatively treated with no known active disease present and no treatment administered for the last 3 years
- •3.3 General Medical Exclusion Criteria
- •3.3.1 Subjects known to have chronic or active hepatitis B or C infection with impaired hepatic function (ineligible if AST and ALT > 3.0 x ULN).
- •3.3.2 History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with study participation or study drug administration or may interfere with the conduct of the study or interpretation of study results
- •3.3.3 Male subject who is not willing to use adequate contraception upon enrollment into this study and for 6 months following the last dose of study agents
- •3.3.4 Female subject (of childbearing potential, post-menopausal for less than 6 months, not surgically sterilized, or not abstinent) who is not willing to use an oral, patch or implanted contraceptive, double-barrier birth control, or an IUD during the course of the study and for 6 months following the last dose of second-line treatment
- •3.3.5 Female subject who is breast-feeding or who has positive serum pregnancy test 72 hours prior to enrollment
- •3.3.6 Any of the following concurrent severe and/or uncontrolled medical conditions within 24 weeks of enrollment which could compromise participation in the study:
- •Unstable angina pectoris
- •Symptomatic congestive heart failure
- •Myocardial infarction <= 6 months prior to registration and/or randomization
- •Serious uncontrolled cardiac arrhythmia
- •Uncontrolled diabetes
- •Active or uncontrolled infection
- •Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
- •Chronic renal disease
- •3.3.7 Patients unwilling to or unable to comply with the protocol
- •3.3.8 Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech/Roche sponsored cancer study
研究组 & 干预措施
Pertuzumab plus Erlotinib Hydrochloride
Experimental
Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
Erlotinib hydrochloride 150 mg/day by mouth
干预措施: Pertuzumab (Drug)
Pertuzumab plus Erlotinib Hydrochloride
Experimental
Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
Erlotinib hydrochloride 150 mg/day by mouth
干预措施: Erlotinib (Drug)
结局指标
主要结局
Overall Response Rate by RECIST Criteria
时间窗: CT imaging every 9 weeks while on protocol
次要结局
- Overall Survival (OS)(1 year)
- Progression-free Survival (PFS)(9 weeks)
- No. of Events of Drug-related Toxicity(3 weeks)
- Quality of Life (QoL)(3 weeks)
- Proportion of Participants With 50% Decrease in Tumor Marker(3 weeks)
研究者
George Albert Fisher
Associate Professor of Medicine
Stanford University
研究点 (1)
Loading locations...
相似试验
终止
2 期
Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic CancerPancreatic CancerNCT00564720Hellenic Oncology Research Group140
已完成
2 期
Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic CancerMetastatic Pancreatic CancerNCT01303029Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)120
已完成
1 期
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic CancerAdvanced Pancreatic CancerNCT01010945OSI Pharmaceuticals19
进行中（未招募）
2 期
Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior LazertinibNon-small Cell Lung CancerNCT05786430Yonsei University87
已完成
2 期
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver CancerAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver CancerNCT00365391National Cancer Institute (NCI)27